News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,697 Results
Type
Article (14175)
Company Profile (282)
Press Release (251240)
Section
Business (79503)
Career Advice (153)
Deals (13231)
Drug Delivery (35)
Drug Development (50437)
Employer Resources (31)
FDA (5713)
Job Trends (5129)
News (144397)
Policy (10037)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (911)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21630)
ALS (57)
Alzheimer's disease (812)
Antibody-drug conjugate (ADC) (79)
Approvals (5719)
Artificial intelligence (102)
Autoimmune disease (8)
Automation (5)
Bankruptcy (103)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (37)
Biotechnology (232)
Bladder cancer (40)
Brain cancer (19)
Breast cancer (135)
Cancer (1184)
Cardiovascular disease (95)
Career advice (132)
Career pathing (2)
CAR-T (102)
Cell therapy (294)
Cervical cancer (5)
Clinical research (40740)
Collaboration (474)
Compensation (204)
Complete response letters (13)
COVID-19 (1031)
CRISPR (34)
C-suite (131)
Cystic fibrosis (75)
Data (1236)
Denatured (11)
Depression (28)
Diabetes (113)
Diagnostics (1285)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (75)
Drug pricing (27)
Drug shortages (3)
Duchenne muscular dystrophy (65)
Earnings (29435)
Editorial (16)
Employer branding (4)
Employer resources (29)
Events (47950)
Executive appointments (383)
FDA (6276)
Featured Employer (32)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (437)
Gene editing (82)
Generative AI (9)
Gene therapy (218)
GLP-1 (344)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6589)
Huntington's disease (21)
IgA nephropathy (19)
Immunology and inflammation (72)
Indications (16)
Infectious disease (1087)
Inflammatory bowel disease (109)
Inflation Reduction Act (8)
Influenza (16)
Intellectual property (52)
Interviews (17)
IPO (7260)
IRA (11)
Job creations (862)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (198)
Leadership (2)
Legal (1388)
Liver cancer (30)
Lung cancer (169)
Lymphoma (78)
Machine learning (1)
Management (7)
Manufacturing (110)
MASH (46)
Medical device (2585)
Medtech (2586)
Mergers & acquisitions (6233)
Metabolic disorders (343)
Multiple sclerosis (47)
NASH (13)
Neurodegenerative disease (53)
Neuropsychiatric disorders (22)
Neuroscience (1160)
NextGen: Class of 2025 (2014)
Non-profit (852)
Northern California (1436)
Now hiring (21)
Obesity (180)
Opinion (99)
Ovarian cancer (50)
Pain (39)
Pancreatic cancer (49)
Parkinson's disease (98)
Partnered (6)
Patents (100)
Patient recruitment (59)
Peanut (35)
People (25438)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14377)
Phase II (18950)
Phase III (11984)
Pipeline (592)
Podcasts (43)
Policy (34)
Postmarket research (853)
Preclinical (6019)
Press Release (30)
Prostate cancer (50)
Psychedelics (35)
Radiopharmaceuticals (211)
Rare diseases (265)
Real estate (1415)
Recruiting (12)
Regulatory (8514)
Reports (14)
Research institute (937)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (2)
RSV (10)
Schizophrenia (54)
Series A (85)
Series B (52)
Service/supplier (1)
Sickle cell disease (37)
Southern California (1277)
Special edition (11)
Sponsored (11)
Startups (1969)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (32)
United States (11383)
Vaccines (199)
Venture capitalists (27)
Webinars (7)
Weight loss (101)
Women's health (14)
Worklife (2)
Date
Today (93)
Last 7 days (357)
Last 30 days (1736)
Last 365 days (20214)
2025 (3748)
2024 (20564)
2023 (22416)
2022 (26825)
2021 (27818)
2020 (23368)
2019 (16235)
2018 (11746)
2017 (13755)
2016 (11854)
2015 (14353)
2014 (10396)
2013 (7490)
2012 (7550)
2011 (7616)
2010 (7430)
Location
Africa (148)
Alabama (37)
Alaska (2)
Arizona (50)
Arkansas (5)
Asia (17155)
Australia (2905)
California (3287)
Canada (1012)
China (291)
Colorado (127)
Connecticut (140)
Delaware (84)
Europe (36918)
Florida (383)
Georgia (98)
Idaho (16)
Illinois (200)
India (7)
Indiana (82)
Iowa (1)
Japan (65)
Kansas (58)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (427)
Massachusetts (2604)
Michigan (68)
Minnesota (128)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (14)
New Hampshire (13)
New Jersey (831)
New Mexico (11)
New York (904)
North Carolina (502)
North Dakota (4)
Northern California (1436)
Ohio (102)
Oklahoma (8)
Oregon (21)
Pennsylvania (625)
Puerto Rico (1)
Rhode Island (13)
South America (207)
South Carolina (3)
Southern California (1277)
Tennessee (24)
Texas (369)
Utah (47)
Virginia (65)
Washington D.C. (27)
Washington State (307)
Wisconsin (13)
265,697 Results for "kyn therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
December 18, 2024
·
3 min read
Drug Development
Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
Kynexis announced today that the first healthy volunteers have been dosed in its first-in-human phase 1 study of KYN-5356. KYN-5356, a clinical-stage small molecule targeting a key enzyme in the kynurenine pathway known as KAT-II, is being developed for cognitive impairment associated with schizophrenia (CIAS).
January 4, 2024
·
1 min read
Business
Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases
Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced the formation of its distinguished Scientific Advisory Board.
May 29, 2024
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Kynexis Launched to Advance Precision Therapeutics for Brain Diseases
Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, launched with €57 million in Series A financing led by Forbion, with participation from Ysios Capital and Sunstone Life Science Ventures.
November 7, 2023
·
4 min read
Layoffs
Repare Therapeutics to Cut Staff Again, This Time by 75%
The latest Repare Therapeutics layoffs will include its chief medical officer and could leave the biotech with fewer than 35 employees as it works to advance two Phase I clinical programs.
February 25, 2025
·
2 min read
·
Angela Gabriel
Genetown
Kyn Therapeutics Rebrands as Ikena Oncology, Reflecting Next Phase of Growth
Kyn Therapeutics, a clinical-stage biotechnology company, today announced it is rebranding to Ikena Oncology.
December 3, 2019
·
5 min read
Press Releases
Dr. Falk Pharma Acquires Kynos Therapeutics, Adding Acute Pancreatitis as a Therapeutic Focus and Further Strengthening Its Development Portfolio
October 29, 2024
·
4 min read
Press Releases
Allogene Therapeutics Announces Participation in March Investor Conference
February 26, 2025
·
2 min read
Business
Kyn Therapeutics Appoints Douglas Carlson as Chief Financial Officer
Kyn Therapeutics today announced that it is expanding its management team with the appointment of Douglas Carlson as its chief financial officer.
February 4, 2019
·
3 min read
1 of 26,570
Next
